Intravitreal Bevacizumab Versus Posterior Sub-Tenon Triamcinolone Acetonide for Treating Diabetic Macular Edema
Key facts
- Who runs it
- Muhammad Aamir Latif
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 46 people enrolled
- Started
- 1 Oct 2025
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Bevacizumab Intravitreal Injection
- Triamcinolone Acetonide Injection
- Record updated
- 12 November 2026
Who can take part
- Age
- 25 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Patients of either gender
- Aged 25-75 years
- With DME for more than three months
- CMT >300 μm
Who cannot take part
- Patients with a previous history of intravitreal bevacizumab
- Previous intraocular surgery
- Previous focal/grid laser treatment
- Ocular trauma
- Media opacities (dense cataract or corneal opacity)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Local data comparing the effects of intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide on central macular thickness (CMT) in patients with diabetic macular edema (DME) are scarce. Therefore, the present study was undertaken to evaluate and compare the short-term anatomical outcomes of these two treatments in terms of CMT reduction.
The 2 groups in the trial
- Bevacizumab-GroupTreatment being tested
Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.
Treatment: Bevacizumab Intravitreal Injection
- Triamcinolone acetonide-GroupTreatment being tested
Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.
Treatment: Triamcinolone Acetonide Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema
- Record updated
- 12 November 2026